NASDAQ:FDMT

4d Molecular Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy FDMT

*Your capital is at risk

$11.60

+1.18 (+11.32%)

At Close: Jun 23, 2026

4D Molecular Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 59.15. In total, the insiders bought 30.18M and sold 12.56M FDMT shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	59.15
● Buy	30.18M shares
● Sell	12.56M shares
78% Buy Activity Moderate Negative Correlation
Buy Signal High Confidence Mar 25, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 59.15. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (78% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 22, 2026 Sell	Common Stock S-Sale	Kirn David See Remarks	Officer	114 746 Value: $1.20M
Jun 17, 2026 Buy	Stock Option (Right to Buy) A-Award	Chacko Jacob Director	Director	50 000 Value: $471.0K
Jun 17, 2026 Buy	Stock Option (Right to Buy) A-Award	Miller-rich Nancy Director	Director	50 000 Value: $471.0K
Jun 17, 2026 Buy	Stock Option (Right to Buy) A-Award	Theuer Charles Director	Director	50 000 Value: $471.0K
Jun 17, 2026 Buy	Stock Option (Right to Buy) A-Award	Tomasello Shawn Director	Director	50 000 Value: $471.0K
Jun 17, 2026 Buy	Stock Option (Right to Buy) A-Award	Gray Susannah Director	Director	50 000 Value: $471.0K
Jun 17, 2026 Buy	Stock Option (Right to Buy) A-Award	Milligan John F Director	Director	75 000 Value: $706.5K
Jun 17, 2026 Buy	Stock Option (Right to Buy) A-Award	Sblendorio Glenn Director	Director	50 000 Value: $471.0K
Jun 01, 2026 Sell	Common Stock S-Sale	Kirn David See Remarks	Officer	1 922 Value: $19.3K
Mar 25, 2026 Buy	Stock Option (Right to Buy) A-Award	Kirn David Chief Executive Officer	CEO / President	750 000 Value: $7.41M
Mar 25, 2026 Buy	Stock Option (Right to Buy) A-Award	Bizily Scott Chief Legal Officer	Officer	217 000 Value: $2.14M
Mar 25, 2026 Buy	Stock Option (Right to Buy) A-Award	Simms Christopher Paul See Remarks	Officer	219 000 Value: $2.16M
Mar 20, 2026 Buy	Restricted Stock Units M-Exempt	Gupta Ashoo Vp, Finance And Controller	Officer	221 Value: $2K
Mar 20, 2026 Buy	Restricted Stock Units M-Exempt	Gupta Ashoo Vp, Finance And Controller	Officer	865 Value: $7K
Mar 20, 2026 Buy	Common Stock M-Exempt	Gupta Ashoo Vp, Finance And Controller	Officer	865 Value: $7K
Mar 20, 2026 Buy	Common Stock M-Exempt	Gupta Ashoo Vp, Finance And Controller	Officer	221 Value: $2K
Mar 20, 2026 Sell	Common Stock S-Sale	Gupta Ashoo Vp, Finance And Controller	Officer	80 Value: $689
Mar 20, 2026 Sell	Common Stock S-Sale	Gupta Ashoo Vp, Finance And Controller	Officer	310 Value: $3K
Jan 05, 2026 Buy	Stock Option (Right to Buy)	Sblendorio Glenn Director	Director	11 250 Value: $31.1K
Jan 05, 2026 Buy	Stock Option (Right to Buy) A-Award	Sblendorio Glenn Director	Director	45 000 Value: $328.5K
Dec 20, 2025 Buy	Restricted Stock Units M-Exempt	Gupta Ashoo Vp, Finance And Controller	Officer	220 Value: $3K
Dec 20, 2025 Buy	Restricted Stock Units M-Exempt	Gupta Ashoo Vp, Finance And Controller	Officer	866 Value: $10.0K
Dec 20, 2025 Buy	Common Stock M-Exempt	Gupta Ashoo Vp, Finance And Controller	Officer	866 Value: $10.0K
Dec 20, 2025 Buy	Common Stock M-Exempt	Gupta Ashoo Vp, Finance And Controller	Officer	220 Value: $3K
Dec 20, 2025 Sell	Common Stock S-Sale	Gupta Ashoo Vp, Finance And Controller	Officer	79 Value: $686

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT 4D MOLECULAR THERAPEUTICS, INC.

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; ...

Read Full Profile Here